WHO Issues Concern Over Severe Lack of Weight-Loss Medications
Under one in 10 individuals who could benefit from weight-loss injections like Wegovy are able to get them, states the World Health Organization as it publishes its first guidance on the therapies.
Given over a billion individuals worldwide now living with obesity, it is calling for increased and just access to these injectable treatments.
Based on projections, in excess of 2,000,000,000 will be obese by 2030 unless action is taken.
"The latest guidelines affirms that obesity is a lifelong illness that can be treated with holistic and lifelong treatment," said the agency's head Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and supply-chain constraints are significant obstacles to widespread access to the treatments that can assist patients in reducing substantial weight, notes the agency.
Weight-Loss Drug Scarcity
Despite the present most optimistic outlook, the supply of these medications could only cover about 100 million people – less than 10% of eligible patients, according to the WHO.
The recommendation urges nations and manufacturers to widen access, via approaches such as licensing agreements.
A patent on a key compound – the primary component of Novo Nordisk's Wegovy – is due to expire in multiple nations in 2026.
The Way Weight-Loss Jabs Work
These medications mimick a biological compound to delay gastric emptying, curb appetite and enhance feelings of fullness so people consume fewer calories.
Patients usually begin shedding pounds in the initial weeks of starting on the regular doses.
Research indicates people may put most of the weight back on within a year of stopping the drug, when their normal hunger return.
To be carrying excess weight elevates your risk for contracting diseases, such as diabetes, cardiovascular issues, brain attack, and specific malignancies.
Obesity concerns individuals in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, according to the health agency.
